Ara-C phosphorylation and Ara-C deamination was measured in vitro, using intact marrow myeloblasts from 25 patients with previously untreated acute myeloid leukaemia. At Ara-C concentrations above 10 μM there was no longer a linear relationship of phosphorylation to Ara-C concentration. Ara-U production was measured by sampling the incubation medium. This method showed greater Ara-U production than previous methods sampling the cell pellet alone. However, Ara-CTP/Ara-U ratios from intact myeloblasts were much higher than those recorded in studies using lysed myeloblasts. Using 1 μM Ara-C, a concentration representative of in vivo concentrations, deamination and phosphorylation were related to therapeutic response to Ara-C-containing drug regimens. There was no significant correlation of these variables with response, although 5/16 non-responders had low Ara-C phosphorylation (<1.5 pmol/106 cells/45 min/l pm Ara-C) compared with 0/9 responders. Measuring deaminase activity did not help in selecting non-responders. Even in patients with low phosphorylation increasing Ara-C concentration increased Ara-CTP levels proportionally, but up to 10 times conventional doses may be necessary to exceed endogenous dCTP levels.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Armentrout SA, Burns CP (1976) Cytosine arabinoside as a single agent in the therapy of adult care leukaemia. Am J Med Sci 268: 163–168
Bodey GP, Freireich EJ, Monto RW, Hewlett JS (1969) Cytosine arabinoside (NSC-63878) therapy for acute leukaemia in adults. Cancer Chemother Rep 53: 59–66
Camiener GW (1967) Studies of the enzymatic deamination of cytosine arabinoside-II. Properties of the deaminase of human liver. Biochem Pharmacol 16: 1681–1689
Chou TC, Arlin A, Clarkson BD, Philips FS (1977) Metabolism of 1-β-d-arabinofuranosylcytosine in human leukaemic cells. Cancer Res 37: 3561–3570
Coleman CN, Stoller RG, Drake JC, Chabner BA (1975) Deoxycytidine kinase: properties of the enzyme from human leukaemic granulocytes. Blood 46: 791–803
Dicioccio RA, Srivastava BIS (1977) Kinetics of inhibition of deoxynucleotide polymerising enzyme activities from normal and leukaemic human cells by 9-β-d-arabinofuranosyladenine 5-triphosphate. Eur J Biochem 79: 411–418
Durham JP, Ives DH (1970a) Deoxycytidine kinase. II. Purification and properties of the calf thymus enzyme,. J Biol Chem 245: 2276–2284
Durham JP, Ives DH (1970b) Deoxycytidine kinase. III. Kinetics and allosteric regulation of the calf thymus enzyme. J Biol Chem 245: 2285–2294
Hall TC (1971) Selecting drug regimens in human leukaemia. Prediction of response in cancer therapy. Natl Cancer Inst Monogr 34: 145–151
Harris AL, Grahame-Smith DG (1980) Variation in sensitivity of DNA synthesis to Ara-C in acute myeloid leukaemia. Br J Haematol 45: 371–379
Harris AL, Potter C, Bunch C, Boutagy J, Harvey DJ, Grahame-Smith DG (1979) Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. Br J Clin Pharmacol 8: 219–227
Hart JS, Ho DH, George SL, Salem P, Gohlieb JA, Frei E III (1972) Cytokinetic and molecular pharmacology studies of arabinosylcytosine in metastatic melanoma. Cancer Res 32: 2711–2716
Hederson JF, Brox LW, Fraser JH, Lomax CA, McCoy EE, Snyder F, Zombor G (1975) Models and methods for biochemical studies of resistance in man. Pharmacological basis of cancer chemotherapy. Williams & Wilkins, Baltimore, pp 663–680
Kessel D, Hall TC, Rosenthal D (1969) Uptake and phosphorylation of cytosine arabinoside by normal and leukaemic blood cells in vitro. Cancer Res 29: 459–463
Kreiss W, Hession C, Soricelli A, Scully K (1977) Combinations of tetrahydouridine and cytosine arabinoside in mouse tumours. Cancer Treat Rep 61: 1355–1364
Mauer AM, Fisher V (1962) Comparison of the proliferative capacity of acute leukaemia cells in marrow and in blood. Nature 193: 1085
Randerath K, Randerath E (1966) Ion-exchange thin-layer chromatography. XV. Preparation properties and applications of paper-like PE1-cellulose sheets. J Chromatogr 22: 110–117
Smyth JF, Robins AB, Leese LL (1976) The metabolism of cytosine arabinoside as a predictive test for clinical response to the drug in acute myeloid leukaemia. Eur J Cancer 12: 567–575
Stuart DC, Burke PJ (1971) Cytidine deaminase and development of resistance to arabinosylcytosine. Nature New Biol 233: 109–110
Stoller RG, Coleman CN, Chang P, Chabner BA (1975) Biochemical pharmacology of cytidine analog metabolism in human leukaemic cells. In: Clemmesen J, Yohn DS (eds) Comparative leukaemia research. Bibl Haematol 43: 531–533
Tattersall MNH, Ganeshaguru K, Hoffbrand AV (1974) Mechanism of resistance of human acute leukaemic cells to cytosine arabinoside. Br J Haematol 27: 39–46
Thorell B (1947) Studies on the formation of cellular substances during blood cell production. Acta Med Scand [Suppl 200]
About this article
Cite this article
Harris, A.L., Grahame-Smith, D.G. The relationship of Ara-C metabolism in vitro to therapeutic response in acute myeloid leukaemia. Cancer Chemother. Pharmacol. 9, 30–35 (1982). https://doi.org/10.1007/BF00296758
- Cancer Research
- Linear Relationship
- Method Sampling
- Myeloid Leukaemia
- Cell Pellet